Table 1. Patient characteristics.
| Variable | IPAH (n=27) | Controls (n=16) | P |
|---|---|---|---|
| Age [years] | 50.0 (41.0-65.0) | 54.0 (37.0-60.5) | 0.76 |
| Sex [males] | 9 (33%) | 5 (31%) | 0.84 |
| BMI [kg/m2] | 23.0 (21.0-26.0) | 27.3 (22.3-28.3) | 0.02 |
| Total cholesterol [mmol/l] | 4.1 (3.6-4.7) | 4.7 (4.6-5.3) | 0.007 |
| LDL-cholesterol [mmol/l] | 2.4 (1.7-2.8) | 2.7 (2.5-3.5) | 0.03 |
| HDL-cholesterol [mmol/l] | 1.3 (1.1-1.5) | 1.6 (1.3-1.8) | 0.01 |
| Triglycerides [mmol/l] | 1.0 (0.8-1.4) | 1.1 (0.9-1.4) | 0.7 |
| Diabetes | 4 (15%) | 0 | 0.28 |
| Systemic arterial hypertension | 10 (37%) | 8 (50%) | 0.61 |
| Smoking | 0 | 0 | - |
| hsCRP [mg/dl] | 2.4 (1.2-8.2) | 1.1 (0.7-2.2) | 0.004 |
| Creatinine [umol/l] | 80.0 (73.0-98.0) | 68.5 (59.0-88.5) | 0.02 |
| Drugs taken before entering the study | |||
| Statins | 9 (33%) | 6 (38%) | 0.96 |
| Diuretics | 12 (44%) | 0 | 0.005 |
| ACEI | 6 (22%) | 6 (38%) | 0.47 |
| Beta blockers | 8 (30%) | 6 (38%) | 0.80 |
| CCB | 8 (30%) | 2 (12.5%) | 0.36 |
| Vitamin K antagonist* | 6 | 0 | - |
| Hemodynamic data | |||
| PA mean pressure [mmHg] | 54.0 (44.3-66.3) | 11.0 (9.5-13.0) | <0.001 |
| RA pressure [mmHg] | 8.0 (5.0-13.0) | 2.0 (2.0-3.0) | <0.001 |
| PAW mean pressure [mmHg] | 8.0 (4.5-11.3) | 7.5 (5.5-9.0) | 0.36 |
| Ao mean pressure [mmHg] | 90.0 (79.0-96.8) | 100.0 (94.0-102.0) | 0.02 |
| Cardiac index [l/min/m2] | 1.6 (1.4-1.9) | 2.7 (2.7-2.8) | <0.001 |
| Estimated oxygen consumption (ml/min) | 187.5 (176.2-203.1) | 180.6 ( 160.9 - 270.6) | 0.58 |
| PVR [WU] | 15.9 (11.3-20.9) | 0.7 (0.4-1.3) | <0.001 |
*
only patients with known IPAH were treated with vitamin K antagonists before enrolment to the study
ACEI - angiotensin converting enzyme inhibitor, BMI - body mass index, CCB - calcium channel blockers, HDL - high density lipoprotein, LDL - low density lipoprotein, PA - pulmonary artery, PAW - pulmonary artery wedge, PVR - pulmonary vascular resistance, RA - right atrium, WU - Wood Units